Genmab sees big potential in epcoritamab – expects EU approval this year
CEO Jan van de Winkel considers it a milestone that the second Genmab-owned product is now on the US market.
by MARKETWIRE, translated by kristoffer grønbæk & daniel pedersen
Genmab takes an important step forward by winning US approval for epcoritamab, which can now be used for third-line treatment of diffuse large B cell lymphoma (DLBCL).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst estimates USD 3.5bn peak sales for new Genmab drug
For subscribers
FDA approves cancer drug Epkinly from Genmab and Abbvie
For subscribers
